Investigation of Aptinyx Inc.

Aptinyx Inc. (APTX)’s Drug Fails to Meet Primary Endpoint

On January 16, 2019, Aptinyx announced that its drug, NYX-2925, did not achieve statistically significant separation from the placebo on a primary end point in its phase 2 trial. On this news, shares of Aptinyx fell $11.85, or 67%, to close at $5.98. The stock has yet to recover and currently trades at around $3.50, a 78% decline from its IPO price.

Send us a message for more information.

Protect your investments.

Sign up for free investment monitoring.

Stock Watch members receive free investment monitoring and notifications.  

Leave your details to get started

Ticker + Amount
This field is for validation purposes and should be left unchanged.